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A B S T R A C T
Objectives: The overall death toll from COVID-19 in Africa is reported to be low but there is little
individual-level evidence on the severity of the disease. This study examined the clinical spectrum and
outcome of patients monitored in COVID-19 care centres (CCCs) in two West-African countries.
Methods: Burkina Faso and Guinea set up referral CCCs to hospitalise all symptomatic SARS-CoV-2
carriers, regardless of the severity of their symptoms. Data collected from hospitalised patients by
November 2020 are presented.
Result: A total of 1,805 patients (64% men, median age 41 years) were admitted with COVID-19. Symptoms
lasted for a median of 7 days (IQR 4–11). During hospitalisation, 443 (25%) had a SpO2 < 94% at least once,
237 (13%) received oxygen and 266 (15%) took corticosteroids. Mortality was 5% overall, and 1%, 5% and
14% in patients aged <40, 40–59 and 60 years, respectively. In multivariable analysis, the risk of death
was higher in men (aOR 2.0, 95% CI 1.1; 3.6), people aged 60 years (aOR 2.9, 95% CI 1.7; 4.8) and those
with chronic hypertension (aOR 2.1, 95% CI 1.2; 3.4).
Conclusion: COVID-19 is as severe in Africa as elsewhere, and there must be more vigilance for common
risk factors such as older age and hypertension.
© 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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As of 05 May 2021, it was estimated that 153 million people had
een infected with SARS-CoV-2 and that COVID-19 had killed 3.2
illion people worldwide. Africa accounted for 3% of deaths from
OVID-19, although 17% of the world’s population lives there.
urope (10% of world population, 34% of deaths from COVID-19)
nd North America (4% of world population, 19% of deaths from
OVID-19) have been impacted comparatively much higher (WHO
oronavirus (COVID-19) Dashboard, n.d.). Therefore, the death toll
rom COVID-19 seemed lower in Africa than in Europe and North
merica, although some predictions indicated the opposite
Martinez-Alvarez et al., 2020). This may have been due to the
eterogeneity of systems for reporting cases and causes of death,
he level of preparedness in a continent that has faced threatening
pidemics in the recent past, or differences in environmental
haracteristics, circulating strains or population susceptibility
Galloway et al., 2020; Nagai et al., 2020; Price-Haywood et al.,
020; Williamson et al., 2020). To study this latter point, it would
e useful to verify whether the clinical presentation, mortality and
actors associated with COVID-19 are similar in Africa to those
escribed in other continents. There have been a few retrospective
opulation or hospital-based cohorts reporting mortality rates
rom COVID-19 in Africa so far, but no cohorts that provide
ndividual-level prospective evidence on the severity of the disease
Abdela et al., 2020; Boulle et al., 2020; El Aidaoui et al., 2020;
limian et al., 2020; Kirenga et al., 2020; Mekolo et al., 2021;
achega et al., 2020). This study reports prospectively collected
linical data on patients hospitalised in the COVID-19 referral care
entres of two West African countries between March and
ovember 2020.
ethods
articipants, settings and follow-up
Burkina Faso and Guinea, two West African countries,
ecided at the start of the COVID-19 pandemic to accommodate
veryone detected as carriers of SARS-CoV-2 in specific centres,
hether asymptomatic or symptomatic, and in the latter case
egardless of the intensity of their symptoms. The Ministries of
ealth in the two countries set up the COVID-19 referral care
entres (CCCs) in collaboration with the non-governmental
ssociation ALIMA (The Alliance for International Medical
ction). In Guinea, the CCC was opened at the Donka hospital
n Conakry. In Burkina Faso, two CCCs were opened at the
engandogo and Clinique Princesse Sarah hospitals, in Ouaga-
ougou. This study describes the data collected from all people
ospitalised with symptomatic COVID-19 and a positive RT-PCR
ARS-CoV-2 test in each of these three centres. Those placed in
solation at the centres and asymptomatic were excluded from
his study. The study period was between 01 April and 04
ovember 2020 in Guinea; and between 01 March and 12
ovember 2020 in Burkina Faso.
are and follow-up
All people received basic care for COVID-19, as defined in the
ecommendations of the ministries of health of the two countries.
o additional medical action or treatment was introduced for
for 3 days then decreased over a total of 10 days), anticoagulant
treatment (enoxaparin 100 IU/kg twice a day) and broad-spectrum
antibiotic therapy, of variable indication depending on the period
and treating physician’s decision.
Throughout the study, the anti-SARS-CoV-2 treatment recom-
mended in the two countries consisted of dual therapy combining
5 days of azithromycin (500 mg at day 1 and then 250 mg/day) with
10 days of hydroxychloroquine (200 mg x tds). In Guinea,
physicians had the choice of alternately using either hydroxy-
chloroquine as monotherapy, lopinavir/ritonavir (200/50 mg bd for
10 days) as monotherapy or lopinavir/ritonavir in combination
with hydroxychloroquine and azithromycin.
Each of the three centres had an intensive care unit, allowing
patients on oxygen to be closely monitored and non-invasive or
mechanical ventilation to be used if required.
Data
Data were recorded using the WHO COVID-19 rapid core case
report form (CRF) (Global COVID-19 clinical platform: rapid core
case report form (CRF), n.d.). In the context of the three urgently-
established CCCs, the data were first collected on hard copy CRF
and subsequently entered into an electronic database. The
variables considered essential for the analysis were then
monitored and the source data verified. Only these variables
are presented in this article. The variables were: patient
verification (exhaustivity of the patient list); sex; age; comor-
bidities; date of first symptoms; signs, symptoms, measurement
of pulse oximetry (SpO2) at baseline and during follow-up;
oxygen therapy, anti-infectious treatments, corticosteroid thera-
py; and vital status at the end of follow-up. Radiological data, and
biological data other than the result of the initial SARS-CoV-2 test
were not monitored.
Statistical analysis
The follow-up time was the time between admission to hospital
and death or discharge alive from hospital. There was no post-
discharge follow-up. The primary endpoint was in-hospital death.
The secondary endpoint was COVID-19 clinical worsening, defined
as a combination of an SpO2 < 94% at least once during follow-up
(including at baseline), use of oxygen therapy at any time during
follow-up, or death. The analysis describes the baseline character-
istics, care received during follow-up, outcomes, and factors
associated with COVID-19 clinical worsening or death.
The Kaplan Meier method was used to estimate the probability
of occurrence of the primary and secondary endpoints over time,
overall and by sex, age category, and presence or absence of the
main comorbidities. Univariable then multivariable logistic
regression were used to analyse the association between the
primary and secondary endpoints and the following character-
istics: sex, age (<60 vs. 60 years), time between first symptom
and hospitalisation (7 vs. >7 days), chronic hypertension declared
by the patient (yes vs. no), diabetes declared by the patient (yes vs.
no), and initial severity (in three grades, mild, moderate, severe,
according to the May 2020 WHO definitions). Variables associated
with the endpoint with a p < 0.20 in univariable analysis were
included in the multivariable model. The analyses were carried out
using the software R, version 4.0.3articipants in this study. Basic care was similar at the three
entres, including: (i) anti-infective treatment considered to have
n anti-SARS-CoV-2 effect and recommended by the national
uthorities; (ii) oxygen therapy via nasal probe or mask, in the
vent of an SpO2 of <90%; and (iii) the possibility of corticosteroid
herapy (methylprednisolone 120 mg/d or dexamethasone 6 mg/d4
Ethical considerations
The study was approved in Burkina Faso by the Comité
d’Ethique pour la Recherche en Santé (ID number 2020-6-116)
and in Guinea by the Comité National d’Ethique pour la Recherche
en Santé (ID number 069/CNERS/20). The committees of the two6
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The funding sources took no part in designing the study,
collecting, analysing and interpreting data, writing the report or
making the decision to submit the article for publication. MJ, BS
and SJ had access to the raw data. The corresponding author had
full access to all data and the final responsibility for submitting it
for publication.
Results
During the study period, 1,938 people (Guinea: 1,593; Burkina
Faso: 345) were admitted to one of the three CCCs with a positive
SARS-CoV-2 test on nasopharyngeal swab. Of these, 133 were
completely asymptomatic and not included in the analysis. The
remaining 1,805 were included in the analysis (Guinea: 1,593;
Burkina Faso: 212). Their baseline characteristics are detailed in
Table 1; 64% were men and 36% women, and the median age was
41 years (IQR 30–57, range 1–99 years). The two most common
comorbidities were chronic hypertension (21%) and diabetes
(12%). The median weight was 73 kg (IQR 60–85). Height, and
therefore body mass index (BMI), could only be measured in 645
people. In this subgroup, the median BMI was 25 kg/m2 (IQR 22–
29), and 119 (18%) had a BMI of 30 kg/m2. At the time of
admission, symptoms lasted for a median of 7 days (IQR 4–11).
The clinical picture was dominated by signs of lower respiratory
tract involvement, present in 1,110 (61%) patients. Digestive signs
were present in 311 (17%) patients. A total of 177 (10%) patients
had an initially measured SpO2 of 90%, and 177 (10%) were
considered severe from the start on the basis of this SpO2 or other
signs of respiratory severity.
The follow-up characteristics are detailed in Table 2. During
hospitalization, 1,697 people (95%) received at least one specific
treatment recommended by national authorities, and 97 (5%)
received none. The most common treatment was the hydroxy-
chloroquine plus azithromycin combination, received by 1,244
(73%) participants. Between admission and the end of follow-up,
231 people (13%) had a measured SpO2 of <90% at least once, 237
(13%) received oxygen and 266 (15%) received corticosteroids.
The rate of clinical worsening was 31% overall; 24% in women
and 34% in men; 23%, in patients aged <60 years and 57% in those
60 years; 59% in diabetics and 27% in non-diabetics; 51% in
patients with self-declared chronic hypertension and 25% in those
without hypertension.
Overall, 86 (5%) patients died within a median of 5 days (IQR 2–
10) of hospital admission. The final percentage of deaths by group
was: 3% in women and 6% in men; 0%, 1%, 5% and 14% in patients
aged <20, 20–39 years, 40–59 years and 60, years, respectively;
13% in diabetics and 4% in non-diabetics; 12% in patients with
chronic hypertension and 3% in those without hypertension; and
26%, 3% and 2% in patients initially considered to be at a severe,
moderate and mild stage, respectively. Patients aged <60 years at
admission accounted for 38% of death (33/86). For these patients,
median age was 50 years (IQR 41–56), 60% were at a severe stage at
admission and 32% and 36% had diabetes and chronic hyperten-
sion, respectively. In the primary analysis, the risk of death was
significantly higher in men, those aged 60 years, those with
chronic hypertension, and those initially considered to be at a
severe stage. The duration of symptoms prior to admission was not
Table 1
Baseline characteristics (n = 1,805).
Country, n (%)












Chronic hypertension 386 21%
Any otherb 147 8%
Time from first symptom to admission (days), median [IQR]a 7 [4; 11]
Signs and symptoms, n (%)
Fever 38.0 C 297 16%
Fatigue 748 41%
Loss of smell or taste 490 27%
Headache 673 37%
Arthralgia or myalgia 294 16%
Higher respiratory tract symptomsc 425 24%
Any lower respiratory tract symptom 1,110 61%
Cough 833 46%
Dyspnoea 505 28%
Chest pain 294 16%
Any digestive tract symptom 311 17%
Vomiting 156 9%
Diarrhoea 95 5%
Abdominal pain 125 7%
Glasgow <15 21 1%
Other signs or symptomsd 36 2%








N, number; %, percentage; IQR, interquartile range.
 Mild: Symptomatic patients meeting the case definition for COVID-19 without
evidence of viral pneumonia or hypoxia.
 Moderate:
- Adolescent or adult with clinical signs of pneumonia (fever, cough, dyspnoea, fast
breathing) but no signs of severe pneumonia, including SpO2  90% on room air.
- Child with clinical signs of non-severe pneumonia (cough or difficulty breathing +
fast breathing and/or chest indrawing) and no signs of severe pneumonia.
 Severe:
- Adolescent or adult with clinical signs of pneumonia (fever, cough, dyspnoea, fast
breathing) plus one of the following: respiratory rate >30 breaths/min; severe
respiratory distress; or SpO2 < 90% on room air.
- Child with clinical signs of pneumonia (cough or difficulty in breathing) + at least
one of the following: Central cyanosis or SpO2 < 90%; severe respiratory distress
(e.g., fast breathing, grunting, very severe chest indrawing); general danger sign:
inability to breastfeed or drink, lethargy or unconsciousness, or convulsions
(55, 56). Fast breathing (breaths/min): <2 months: 60; 2–11 months: 50; 1–5
years: 40.
a Missing values: sex, n = 3; age, n = 15; time since first symptoms, n = 517.
b Chronic cardiac disease (n = 25, 1%), current smoking (n = 12, 1%), chronic
pulmonary disease (n = 17, 1%), active or previous tuberculosis (n = 23, 1%), asthma
(n = 39, 2%), asplenia (n = 0, 0%), chronic kidney disease (n = 13, 1%), malignant
neoplasm (n = 4, 0%), chronic hepatic disease (n = 19, 1%), chronic neurological
disorder (n = 8, 0%), HIV infection (n = 5, 0%).
c Runny nose, nasal congestion, sneezing.
d Other signs or symptoms: confusion (n = 18, 1%), seizure (n = 6, 0%),
conjunctivitis (n = 7, 0%), skin rash (n = 3, 0%), skin ulcer (n = 1, 0%),
lymphadenopathy (n = 3, 0%), bleeding (n = 1, 0%).
e Adapted from WHO May 2020 interim guidance (WHO, 2020a).countries authorised the use of medical data collection in
accordance with WHO methodology to describe the course of
the COVID-19 disease during routine care, without requesting
signatures for specific consent.47significantly associated with the risk of death (Table 3A, Figure 1
and 2). In the secondary analysis, male patients, those aged 60
years, those with chronic hypertension, and those with diabetes
had a higher risk of clinical worsening (Table 3B, Figure 1 and 2).
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It is believed that this is the first African study describing the
linical presentation and outcomes of COVID-19 among symptom-
tic patients prospectively monitored in specialist hospital care
entres. This study has strengths in that it provides partial answers
o some of the questions surrounding COVID-19 in Africa, and
eaknesses in that it leaves other questions unanswered.
In two West African countries where the policy was to
ospitalise everyone with a positive SARS-Cov-2 RT-PCR test,
egardless of the severity of the clinical picture, 5% of symptomatic
eople who were hospitalised died. Mortality was 14% in patients
aged 60 years and 26% in people with severe respiratory signs on
admission. Although no comparisons can be made between
hospitals in different countries with different hospitalisation
practices and levels of care, these figures are consistent with those
described elsewhere (Lv et al., 2020; Olumade and Uzairue, 2021;
Singer et al., 2020) and strongly suggest that COVID-19 is at least as
serious in Africa as it is in other continents (Boulle et al., 2020;
Elimian et al., 2020; Kirenga et al., 2020; Nachega et al., 2020). If
the reported death toll from COVID-19 is lower in Africa than in
Europe or the USA (Chilimuri et al., 2020; Galloway et al., 2020;
Rossi et al., 2020; Zhou et al., 2020), it is probably not because the
disease is less lethal in Africa. This reasoning is also compatible
with the 2.8%, 9.2% and 13.2% mortality rates reported from
retrospective population or hospital-based cohorts in South Africa,
Nigeria and the Democratic Republic of the Congo (Boulle et al.,
2020; Elimian et al., 2020; Nachega et al., 2020) as well as the 5.6%
of an African meta-analysis (Olumade and Uzairue, 2021).
In the present study, the predominant clinical presentation was
respiratory. Digestive signs and general signs, headaches, myalgia
and asthenia were nevertheless quite frequent, as was a lack of
taste and smell. Mortality was twice as high in people with
hypertension, 2 times higher in men, and 3 times higher in people
aged 60 years. These clinical spectrum and factors associated
with mortality are also consistent with what has been described
elsewhere (Boulle et al., 2020; El Aidaoui et al., 2020; Elimian et al.,
2020; Guan et al., 2020; Huang et al., 2020; Kirenga et al., 2020;
Nachega et al., 2020; Singer et al., 2020; Zhou et al., 2020). They
emphasise the particular severity of the disease in groups at risk, in
Africa as elsewhere, and the need to set up appropriate care to try
to reduce the high mortality rate in these groups.
The first type of appropriate care is oxygen therapy. In the
present study, participants received oxygen therapy when their
SpO2 dropped below 90%, but few people with an SpO2 of between
90% and 93% did. Very few patients also benefited from non-
invasive or invasive ventilation. It can be hypothesised that
expanding the indications for oxygen therapy and increasing
options for ventilation could have reduced mortality (Baker et al.,
2020).
Regarding other ways to improve care, the data is of very limited
value. The anti-infective treatments recommended in both
countries and widely prescribed to patients in this study have
not been proven effective so far (Kaptein et al., 2020; Maisonnasse
et al., 2020; RECOVERY Collaborative Group et al., 2020; Skipper
et al., 2020). The data do not provide any new insights in this
regard. In the present study, a large percentage of patients received
able 2
ollow-up characteristics (n = 1,805).
Vital signs during follow-up, n (%)
Heart rate >110 beats/min at least once 338 19%
Glasgow <15 at least once 37 2%




Care received, n (%)
Specific drugs:a 1,697 95%
Hydroxychloroquine + azithromycin 1,244 73%
Hydroxychloroquine 227 13%
Hydroxychloroquine + azithromycin + lopinavir/ritonavir 212 12%
Hydroxychloroquine + lopinavir/ritonavir 7 0.4%
Lopinavir/ritonavir 7 0.4%
No specific drugs 97 5%
Other drugs
Other antibiotics 1,491 83%
Corticosteroids 266 15%
Systemic anticoagulation 315 17%
Received oxygen therapy 237 13%
WHO ordinal scale (higher grade)b
Stage 4: Oxygen by mask or nasal prongs 151 64%
Stage 5: Non-invasive ventilation or high-flow oxygen 83 35%
Stage 6: Intubation and mechanical ventilation 3 1%
Admitted to intensive care unit 275 15%
Final vital status
Death, n (%) 86 5%
Time from admission to death (days), median [IQR] 5 [2; 10]
Alive, n (%) 1,719 95%
Time from admission to discharge (days), median [IQR]a 11 [8; 16]
Combined secondary outcome
Death or oxygen therapy or oxygen saturation <94%, n (%) 552 31%
, number; %, percentage; IQR, interquartile range.
a Missing values: Specific drugs, n = 11; time from admission to discharge, n = 1.
b See reference (WHO, 2020b).
able 3A
actors associated with the risk of death.
Univariable Multivariable
n/N % cOR 95% CI p n/N % aOR 95% CI p
Sex Female 18/651 3% – – – 18/643 3% – – –
Male 68/1,151 6% 2.2 [1.3; 3.8] 0.002 68/1,144 6% 2.0 [1.1; 3.6] 0.019
Age <60 years 33/1,402 2% – – – 33/1,400 2% – – –
60 years 53/388 14% 6.5 [4.2; 10.4] <0.001 53/387 14% 2.9 [1.7; 4.8] <0.001
Diabetes No 58/1,586 4% – – – 58/1,570 4% – – –
Yes 28/219 13% 3.9 [2.4; 6.2] <0.001 28/217 13% 1.3 [0.8; 2.3] 0.32
Chronic hypertension No 41/1,419 3% – – – 41/1,403 3% – – –
Yes 45/386 12% 4.4 [2.9; 6.9] <0.001 45/384 12% 2.1 [1.2; 3.4] 0.006
Initial severity gradea Mild 18/867 2% – – – 18/857 2% – – –
Moderate 22/761 3% 1.4 [0.7; 2.7] 0.30 22/753 3% 1.3 [0.7; 2.6] 0.37
Severe 46/177 26% 16.4 [9.4; 30.0] <0.001 46/177 26% 9.0 [5.0; 16.8] <0.001
Time since first symptom 7 days 31/778 4% – – – – – – – –
>7 days 27/510 5% 1.4 [0.8; 2.3] 0.28 – – – – –
 = total number of patients in the category; n = number of patients in the category who died; CI: confidence interval; cOR: crude odds ratio; aOR: adjusted odds ratio: the OR
r each variable shown in the table was adjusted on the other variables shown in the table.
a See reference (WHO, 2020b).
48
Figure 1. Kaplan Meier estimate of the probability of clinical worsening and death in the overall population.
Figure 2. Kaplan Meier estimate of the probability of clinical worsening and death, according to sex, age, and comorbidities.
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ould be expected based on SpO2 figures, there are no more details
experimental, and it is important for African centres to participate
in trials of new curative treatments.
Figure 2. (Continued)
able 3B
actors associated with the risk of clinical worsening.
Univariable Multivariable
n/N % cOR 95% CI p n/N % aOR 95% CI p
Sex Female 157/651 24% – – – 157/643 24% – – –
Male 394/1,151 34% 1.6 [1.3; 2.0] <0.001 392/1,144 34% 1.6 [1.3; 2.1] <0.001
Age <60 years 327/1,402 23% – – – 326/1,400 23% – – –
60 years 223/388 57% 4.4 [3.5; 5.6] <0.001 223/387 58% 3.1 [2.4; 4.0] <0.001
Diabetes No 423/1,586 27% – – – 420/1,570 27% – – –
Yes 129/219 59% 4.0 [2.9; 5.3] <0.001 129/217 59% 2.3 [1.6; 3.1] <0.001
Chronic hypertension No 356/1,419 25% – – – 354/1,403 25% – – –
Yes 196/386 51% 3.1 [2.4; 3.9] <0.001 195/384 51% 1.7 [1.3; 2.2] <0.001
Time since first symptom 7 days 223/778 29% – – – – – – – –
>7 days 188/510 37% 1.5 [1.1; 1.8] 0.002 – – – – –
 = total number of patients in the category; n = number of patients in the category who had an SpO2 < 94%, received oxygen, or died; CI: confidence interval; cOR: crude odds
atio; aOR: adjusted odds ratio: the OR for each variable shown in the table was adjusted on the other variables shown in the table.n its duration or precise indications. In addition, the data do not
llow comment on anything concerning elaborate management of
he complications of the disease in its inflammatory phase, but
ince substantial resuscitation capacities are limited, there is little
ope for improving survival this way. Hopes for therapy lean more
oward earlier intervention. Treatments of this nature are still5
Finally, this study was also limited as follows. Because it was
carried out at the height of an emergency, the monitoring of
collected data was limited to a small number of key variables to
ensure the analysis provided solid descriptive elements. Since the
number of variables was limited, the analysis of factors associated
with outcomes probably suffered from confusion bias.0
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elsewhere, and this external consistency has the advantage of
increasing confidence that the data are robust. It is therefore
believed that the main results, which are the overall and group
mortality rates, are credible.
In conclusion, COVID-19 is a serious disease in Africa, as it is
elsewhere. Men are more likely to experience complications than
women, and certain common risk factors such as age, diabetes and
hypertension should make us particularly vigilant in the event of
COVID-19 in these countries. Further studies should now focus on
finding ways to reduce mortality from COVID-19 in Africa, overall
and in these at-risk groups.
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